Oddo BHF - SGS SA (SGSN) SGS : Preview S1 – Les devises pèseront sur la marge du S1 – Les effets des initiatives du nouveau management seront plus visibles au S2

Report

Oddo BHF

Eya Drira ...

Geoffroy Michalet

SGS : Preview S1 – Les devises pèseront sur la marge du S1 – Les effets des initiatives du nouveau management seront plus visibles au S2

>Croissance organique résiliente mais marge en baisse au S1 - SGS publiera ses résultats S1 le mercredi 24/07 avant Bourse. Nous attendons qu’ils se situent dans le prolongement des tendances constatées au T1 sur la topline. Pour le T2, nous maintenons notre estimation de croissance organique inchangée à 7.6%e i.e 7.4% sur le S1. Nous tablons sur un effet FX de -4.4%e au T2 i.e -6.5%e au S1 et -3.6%e sur l’année. La croissance devrait être tirée principalem...

20/06/2024 1 FR

Underlying

SGS SA

See profile

CH1256740924 Switzerland

Provider

Oddo BHF

Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.

See profile

Analysts

Eya Drira

Geoffroy Michalet

Other Reports on these Companies

Oddo BHF

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 06/20/2024

Thanks to its business model focused on the growth potential of long-term savings (AM/WM, insurance) in Italy, Intesa Sanpaolo is in a win/win position vis-à-vis the expected interest rate normalisation. Combined with its strong balance sheet and operating efficiency, this should bolster the credibility of the group’s capital plan and ultimately that of its attractive shareholder returns policy which is still not properly priced in. We reiterate our Outperform rating on the stock, wit...

June 20, 2024 June 20, 2024 1 EN

Oddo BHF

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 20/06/2024

Grâce à un business model axé sur le potentiel de croissance de l’épargne LT (AM/WM, assurance) en Italie, IntesaSP jouit d’une position ‘win/win’ pour aborder la phase de normalisation sur les taux d’intérêt. Couplé à sa solidité bilancielle et son efficience opérationnelle, cela devrait permettre au groupe de crédibiliser sa trajectoire de capital et in fine une politique de retour à l’actionnaire attractive encore insuffisamment valorisée. Nous réitérons notre opinion Surperformanc...

June 20, 2024 June 20, 2024 1 FR

Oddo BHF

SGS : H1 preview – Currencies will weigh on the margin in H1 – The effects of the new management’s initiatives will be more visible in H2

>Resilient organic growth but fall in the margin in H1 - SGS will report its H1 results on Wednesday 24 July before trading. We expect them to show a continuation of the top line trend seen in Q1. For Q2, we leave our organic growth estimate unchanged at 7.6%e, i.e. 7.4% in H1. We expect an FX effect of -4.4%e in Q2, i.e. -6.5%e in H1 and -3.6%e over the full year. Growth should be driven mainly by the Industry&Environment (33% of revenues) and Natural reso...

June 20, 2024 June 20, 2024 1 EN

London Stock Exchange Group : Indispensable: a high moat business with improving fundamentals

The Refinitiv acquisition transformed LSEG. The company now offers indispensable services to global financial markets, with a wide moat and sticky clients. Mid-term focus is on integration, driving revenue and margin expansion. CAPEX needs are elevated, however, and could exceed initial projections. Hence, we initiate with a Neutral rating and £ 105 TP. - >LSEG in a nutshell - LSEG is a leading financial services company offering solutions across multiple asset cla...

26m 26m 1 EN

Team Pharma

Team Pharma

ODDO : The macroeconomic environment is not helping the sector

The last few weeks had seen renewed interest in the sector, with stronger volumes, M&A activity and market transactions. Unfortunately, the political context in France has again undermined French biotechs. A large number of clinical results are expected in the next few months (Ose, Aelis, Genfit, Medincell, Trangsene, Abivax, etc.). If successful, these could reinvigorate the sector. In the meantime, we are taking a more decisive stance, increasing the beta of the firms in our sa...

4h / 50m 4h / 50m 1 EN

Team Pharma

Team Pharma

ODDO : L'environnement macro ne favorise pas le secteur

Ces dernières semaines avaient laissé entrevoir un regain d’intérêt pour le secteur avec une hausse des volumes, du M&A et des opérations de marché. Malheureusement le contexte politique français vient à nouveau de pénaliser les biotechs françaises. Un nombre important de résultats cliniques sont attendus dans ces prochains mois (Ose, Aelis, Genfit, Medincell, Trangsene, Abivax…) qui pourraient, en cas de succès, redynamiser le secteur. Dans l’intervalle, nous décidons d’être plu...

5h / 32m 5h / 32m 1 FR

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

SGS : Preview S1 – Les devises pèseront sur la marge du S1 – Les effets des initiatives du nouveau management seront plus visibles au S2

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 06/20/2024

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 20/06/2024

SGS : H1 preview – Currencies will weigh on the margin in H1 – The effects of the new management’s initiatives will be more visible in H2

London Stock Exchange Group : Indispensable: a high moat business with improving fundamentals

ODDO : The macroeconomic environment is not helping the sector

ODDO : L'environnement macro ne favorise pas le secteur

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe